DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Glomerulonephritis - Pipeline Review, H1 2017" report to their offering.
Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Glomerulonephritis - Overview
- Glomerulonephritis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glomerulonephritis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glomerulonephritis - Companies Involved in Therapeutics Development
- Achillion Pharmaceuticals Inc
- Alexion Pharmaceuticals Inc
- Anthera Pharmaceuticals Inc
- Biogen Inc
- BLR Bio LLC
- ChemoCentryx Inc
- Dimerix Bioscience Pty Ltd
- GlaxoSmithKline Plc
- Mallinckrodt Plc
- Omeros Corp
- Pfizer Inc
- Pharmalink AB
- Ra Pharmaceuticals Inc
- Retrophin Inc
- Rigel Pharmaceuticals Inc
- Shire Plc
- Visterra Inc
For more information about this report visit http://www.researchandmarkets.com/research/nxhzbm/glomerulonephritis
